BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Safi F, Roscher R, Bittner R, Schenkluhn B, Dopfer HP, Beger HG. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas 1987;2:398-403. [PMID: 3306667 DOI: 10.1097/00006676-198707000-00006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Tian F, Appert HE, Myles J, Howard JM. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg. 1992;215:350-355. [PMID: 1348409 DOI: 10.1097/00000658-199204000-00008] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 2.7] [Reference Citation Analysis]
2 Muyinda IJ, Park JG, Jang EJ, Yoo BC. KRAS, A Prime Mediator in Pancreatic Lipid Synthesis through Extra Mitochondrial Glutamine and Citrate Metabolism. Int J Mol Sci 2021;22:5070. [PMID: 34064761 DOI: 10.3390/ijms22105070] [Reference Citation Analysis]
3 Dogan M, Algin E, Guven ZT, Baykara M, Kos TF, Bal O, Zengin N. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, neutrophil-platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer? Curr Med Res Opin. 2018;34:857-863. [PMID: 29161926 DOI: 10.1080/03007995.2017.1408579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
4 Appert HE. Composition and production of pancreatic tumor related antigens. Int J Pancreatol 1990;7:13-24. [PMID: 2081918 DOI: 10.1007/BF02924216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.0] [Reference Citation Analysis]
5 Frena A. SPan-1 and Exocrine Pancreatic Carcinoma. The Clinical Role of a New Tumor Marker. Int J Biol Markers 2001;16:189-97. [DOI: 10.1177/172460080101600306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.ssn.2078-6891.2011.021] [Reference Citation Analysis]
7 Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA; NCCN Pancreatic Adenocarcinoma. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010;8:972-1017. [PMID: 20876541 DOI: 10.6004/jnccn.2010.0073] [Cited by in Crossref: 122] [Cited by in F6Publishing: 104] [Article Influence: 11.1] [Reference Citation Analysis]
8 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.1002/ijc.20037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
9 Mauer KR, Lopatin RN, Hoffman WA, Grossman ET, Russo RD. Decrease in a markedly elevated CA19-9 level after stenting of a benign pancreatic ductal stricture. Gastrointest Endosc. 1995;42:261-263. [PMID: 7498694 DOI: 10.1016/S0016-5107(95)70103-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
10 Bedi MM, Gandhi MD, Jacob G, Lekha V, Venugopal A, Ramesh H. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? Indian J Gastroenterol. 2009;28:24-27. [PMID: 19529898 DOI: 10.1007/s12664-009-0005-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
11 Brody JR, Witkiewicz AK, Yeo CJ. The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer. Adv Surg. 2011;45:301-321. [PMID: 21954696 DOI: 10.1016/j.yasu.2011.04.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
12 Adsay NV, Pierson C, Sarkar F, Abrams J, Weaver D, Conlon KC, Brennan MF, Klimstra DS. Colloid (Mucinous Noncystic) Carcinoma of the Pancreas: . The American Journal of Surgical Pathology 2001;25:26-42. [DOI: 10.1097/00000478-200101000-00003] [Cited by in Crossref: 227] [Cited by in F6Publishing: 154] [Article Influence: 11.4] [Reference Citation Analysis]
13 Moral A, Magarzo J. Marcadores tumorales serológicos en cirugía hepatobiliopancreática. Cirugía Española 2004;76:276-83. [DOI: 10.1016/s0009-739x(04)72378-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Angata T, Fujinawa R, Kurimoto A, Nakajima K, Kato M, Takamatsu S, Korekane H, Gao CX, Ohtsubo K, Kitazume S. Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases. Ann N Y Acad Sci. 2012;1253:159-169. [PMID: 22380786 DOI: 10.1111/j.1749-6632.2012.06469.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
15 Grubbs EG, Abdel-Wahab Z, Tyler DS, Pruitt SK. Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer. Ann Surg Oncol 2006;13:1645-54. [PMID: 16957968 DOI: 10.1245/s10434-006-9029-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
16 Audisio RA, Veronesi P, Maisonneuve P, Chiappa A, Andreoni B, Bombardieri E, Geraghty JG. Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma. Surg Oncol 1996;5:49-63. [PMID: 8853239 DOI: 10.1016/s0960-7404(96)80001-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
17 Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019;10:10-27. [PMID: 30834048 DOI: 10.14740/wjon1166] [Cited by in Crossref: 473] [Cited by in F6Publishing: 371] [Article Influence: 236.5] [Reference Citation Analysis]
18 Engle DD, Tiriac H, Rivera KD, Pommier A, Whalen S, Oni TE, Alagesan B, Lee EJ, Yao MA, Lucito MS, Spielman B, Da Silva B, Schoepfer C, Wright K, Creighton B, Afinowicz L, Yu KH, Grützmann R, Aust D, Gimotty PA, Pollard KS, Hruban RH, Goggins MG, Pilarsky C, Park Y, Pappin DJ, Hollingsworth MA, Tuveson DA. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science 2019;364:1156-62. [PMID: 31221853 DOI: 10.1126/science.aaw3145] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 70.0] [Reference Citation Analysis]
19 Archer FJ, Kerr ME, Houston DM. Evaluation of Three Pancreas Specific Protein Assays, TLI(Trypsin-Like Immunoreactivity), PASP (Pancreas Specific Protein) and CA 19-9 (Glycoprotein) for use in the Diagnosis of Canine Pancreatitis. Journal of Veterinary Medicine Series A 1997;44:109-13. [DOI: 10.1111/j.1439-0442.1997.tb01092.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
20 Lamerz R. CA 19–9, GICA (Gastrointestinal Cancer Antigen). In: Sell S, editor. Serological Cancer Markers. Totowa: Humana Press; 1992. pp. 309-39. [DOI: 10.1007/978-1-4612-0401-5_14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
21 Von Rosen A, Linder S, Harmenberg U, Wiechel K. Clinical relevance of tumour markers CA 19-9 and CA-50 in sera from patients with pancreatic duct carcinoma. Surgical Oncology 1992;1:109-13. [DOI: 10.1016/0960-7404(92)90023-e] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
22 Italian Association of Hospital Gastroenterologists and Endoscopists, Italian Association for the Study of the Pancreas, Cystic Pancreatic Neoplasm Study Group; Buscarini E, Pezzilli R, Cannizzaro R, De Angelis C, Gion M, Morana G, Zamboni G, Arcidiacono P, Balzano G, Barresi L, Basso D, Bocus P, Calculli L, Capurso G, Canzonieri V, Casadei R, Crippa S, D'Onofrio M, Frulloni L, Fusaroli P, Manfredi G, Pacchioni D, Pasquali C, Rocca R, Ventrucci M, Venturini S, Villanacci V, Zerbi A, Falconi M. Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms. Dig Liver Dis. 2014;46:479-493. [PMID: 24809235 DOI: 10.1016/j.dld.2013.12.019] [Cited by in Crossref: 74] [Cited by in F6Publishing: 60] [Article Influence: 10.6] [Reference Citation Analysis]
23 Kim B, Lee K, Moon T, Kang P, Lee J, Kim J, Rhee J. How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? Digestive and Liver Disease 2009;41:364-9. [DOI: 10.1016/j.dld.2008.12.094] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
24 Tiriac H, Plenker D, Baker LA, Tuveson DA. Organoid models for translational pancreatic cancer research. Curr Opin Genet Dev 2019;54:7-11. [PMID: 30844513 DOI: 10.1016/j.gde.2019.02.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 11.5] [Reference Citation Analysis]
25 Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol. 2011;2:88-100. [PMID: 22693400 DOI: 10.1007/s13193-011-0042-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 96] [Article Influence: 12.2] [Reference Citation Analysis]
26 Castillo CF, Warshaw AL. Diagnosis and Preoperative Evaluation of Pancreatic Cancer, with Implications for Management. Gastroenterology Clinics of North America 1990;19:915-33. [DOI: 10.1016/s0889-8553(21)00522-7] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
27 Kikuyama M, Kamisawa T, Kuruma S, Chiba K, Kawaguchi S, Terada S, Satoh T. Early Diagnosis to Improve the Poor Prognosis of Pancreatic Cancer. Cancers (Basel). 2018;10. [PMID: 29439461 DOI: 10.3390/cancers10020048] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
28 Kawai S, Suzuki K, Nishio K, Ishida Y, Okada R, Goto Y, Naito M, Wakai K, Ito Y, Hamajima N. Smoking and serum CA19-9 levels according to Lewis and secretor genotypes. Int J Cancer 2008;123:2880-4. [DOI: 10.1002/ijc.23907] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
29 Satake K, Chung Y, Umeyama K, Takeuchi T, Kim YS. The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various serum tumor markers. A retrospective study. Cancer 1991;68:149-52. [DOI: 10.1002/1097-0142(19910701)68:1<149::aid-cncr2820680127>3.0.co;2-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
30 Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-33. [PMID: 25892884 DOI: 10.3748/wjg.v21.i14.4323] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
31 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.issn.2078-6891.2011.021] [Cited by in F6Publishing: 207] [Reference Citation Analysis]
32 Warshaw AL, Swanson RS. Pancreatic cancer in 1988. Possibilities and probabilities. Ann Surg 1988;208:541-53. [PMID: 2461172 DOI: 10.1097/00000658-198811000-00001] [Cited by in Crossref: 132] [Cited by in F6Publishing: 110] [Article Influence: 4.0] [Reference Citation Analysis]
33 Chowdhuri SR, Fetsch P, Squires J, Kohn E, Filie AC. Adenocarcinoma cells in effusion cytology as a diagnostic pitfall with potential impact on clinical management: a case report with brief review of immunomarkers. Diagn Cytopathol 2014;42:253-8. [PMID: 23161830 DOI: 10.1002/dc.22915] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
34 Bloomston M, Bekaii-Saab TS, Kosuri K, Cowgill SM, Melvin WS, Ellison EC, Muscarella P 2nd. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection. Pancreas 2006;33:246-9. [PMID: 17003645 DOI: 10.1097/01.mpa.0000236726.34296.df] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
35 Bilchik A, Miyashiro M, Kelley M, Kuo C, Fujiwara Y, Nakamori S, Monden M, Hoon DSB. Molecular detection of metastatic pancreatic carcinoma cells using a multimarker reverse transcriptase-polymerase chain reaction assay. Cancer 2000;88:1037-44. [DOI: 10.1002/(sici)1097-0142(20000301)88:5<1037::aid-cncr13>3.0.co;2-h] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]